China Biotech Services Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, Group expected to record a net loss attributable to the owners of the Company of approximately HKD 90,000,000. In contrast to the Loss, the Group recorded a net profit attributable to the owners of the Company of approximately HKD 258,087,000 for the corresponding period in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.335 HKD | 0.00% | +3.08% | -56.49% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.49% | 41.26M | |
+22.04% | 88.99B | |
-24.36% | 74.82B | |
+1.06% | 26.63B | |
+3.92% | 17.88B | |
-14.13% | 16.43B | |
+2.02% | 15.77B | |
+76.91% | 13.21B | |
+69.79% | 13.08B | |
+39.29% | 12.9B |
- Stock Market
- Equities
- 8037 Stock
- News China Biotech Services Holdings Limited
- China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023